Treatment for Completers of the Study B7A-MC-MBCM

Completed · Phase 3

Conditions studied: Diabetic Retinopathy

In brief

To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.

Key facts

Study ID
NCT00266695
Run by
Chromaderm, Inc.
People needed
203
Starts
2006-01-01
Expected to finish
2008-08-01
Last updated by the study team
2016-10-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.